APRIL modulators(Tumor necrosis factor ligand superfamily member 13 modulators), BAFF modulators(B-cell-activating factor/B lymphocyte stimulator modulators), IL-11 modulators(interleukin 11 modulators)

+ [1]

Therapeutic Areas

Urogenital DiseasesDigestive System DisordersRespiratory Diseases+ [1]

Active Indication

Fibrosis, LiverRenal fibrosisIdiopathic Pulmonary Fibrosis

Inactive Indication

Nonalcoholic Steatohepatitis

Originator Organization

AKSO Biopharmaceutical, Inc.

Active Organization

AKSO Biopharmaceutical, Inc.

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

100 Clinical Results associated with AB-004

100 Translational Medicine associated with AB-004

100 Patents (Medical) associated with AB-004

Literatures (Medical) associated with AB-004

01 Jun 2022·Arthroscopy, Sports Medicine, and Rehabilitation

Bipolar Radiofrequency Ablation Does Not Result in Full-Thickness Articular Cartilage Penetration: An Ex Vivo Bovine Investigation

Article

Author: Friedman, Darren J ; Krupp, Maxwell J ; Matuska, Andrea M ; Khoury, Anthony N

PurposeTo evaluate the depth of penetration of manufacturer-recommended bipolar radiofrequency (BRF) output in healthy hyaline cartilage.MethodsTwo matched knees from a bovine specimen were harvested for immediate testing. BRF probes were used to treat the articular cartilage in a hydrated noncontact technique employing a 1-mm spacer on patellar, condylar, and trochlear surfaces. Two manufacturer-recommended ablate power settings were evaluated to analyze the effect of varying power outputs on the depth of penetration. Surfaces were randomized and treated with BRF ablate setting 3 (AB-3), 4 (AB-4), or left untreated as a control (12 grids each). Slices were extracted from treatment zones and subjected to fluorescein diacetate and propidium iodide viability stains and analyzed with confocal light microscopy. A general linear model was used to determine whether variables such as ablation setting, cartilage location, and side significantly influenced depth of penetration (DoP) and cartilage thickness (Minitab 19, Chicago, IL). When significance was noted (P < .05), a post hoc-Tukey test was used to investigate specific differences.ResultsAB-3 had a 50.9% lower mean DoP than AB-4 (P = .006). The mean DoP was 237.9 ± 140.6 μm for AB-3 and 484.1 ± 267.0 μm for AB-4. Median DoP values were 243.2 ± 149.5 μm for AB-3, 51.2% lower than the 498.4 ± 286.0 μm for AB-4. The mean maximum DoP for AB-3 was 302.4 ± 167.8 μm, 50.6% lower than AB-4 value of 611.6 ± 299.1 μm. Analysis of the cartilage thickness confirmed there was no difference in overall cartilage thickness used for AB-3 versus AB-4 testing (P = .953).ConclusionsThe RF probe ablate power setting AB-3 demonstrated significantly less articular cartilage depth of penetration than the AB-4 setting in a healthy bovine model.Clinical RelevanceDebridement of chondral lesions with plasma BRF is of clinical interest. The presented study adds basic science information for those considering performing this technique.

01 Feb 2009·The Journal of MicrobiologyQ4 · BIOLOGY

Isolation and characterization of a marine algicidal bacterium against the harmful raphidophyceae Chattonella marina

Q4 · BIOLOGY

Article

Author: Yun Sook Kim ; Seong-Yun Jeong ; Myung-Suk Lee ; Dae-Sung Lee ; Woe Jae Lee

A bacterial strain named AB-4 showing algicidal activity against Chattonella marina was isolated from coastal water of ULjin, Republic of Korea. The isolated strain was identified as Bacillus sp. by culture morphology, biochemical reactions, and homology research based on 16S rDNA. The bacterial culture led to the lysis of algal cells, suggesting that the isolated strain produced a latent algal-lytic compound. Amongst changes in algicidal activity by different culture filtrate volumes, the 10% (100 microl/ml) concentration showed the biggest change in algicidal activity; there, estimated algicidal activity was 95%. The swimming movements of Chattonella marina cells were inhibited because of treatment of the bacterial culture; subsequently, Chattonella marina cells became swollen and rounded. With longer exposure time, algal cells were disrupted and cellular components lost their integrity and decomposed. The released algicide(s) were heat-tolerant and stable in pH variations, except pH 3, 4, and 5. Culture filtrate of Bacillus sp. AB-4 was toxic against harmful algae bloom (HAB) species and nontoxic against livefood organisms. Bacillus sp. AB-4 showed comparatively strong activity against Akashiwo sanguinea, Fibriocapsa japonica, Heterosigma akashiwo, and Scrippsiella trochoidea. These results suggest that the algicidal activity of Bacillus sp. AB-4 is potentially useful for controlling outbreaks of Chattonella marina.

01 May 2007·Journal of EthnopharmacologyQ2 · MEDICINE

Hepatoprotective potential of Aloe barbadensis Mill. against carbon tetrachloride induced hepatotoxicity

Q2 · MEDICINE

Article

Author: K.A. Suri ; B. Singh ; D.K. Gupta ; Sangeeta Shukla ; B.K. Chandan ; A.K. Saxena ; M. Bhadauria ; Jyotsna Suri ; Neelam Sharma

Aloe barbadensis Mill. Syn. Aloe vera Tourn. ex Linn.(Liliaceae) has been used in variety of diseases in traditional Indian system of medicine in India and its use for hepatic ailments is also documented. In the present study an attempt has been made to validate its hepatoprotective activity. The shade dried aerial parts of Aloe barbadensis were extracted with petroleum ether (AB-1), chloroform (AB-2) and methanol (AB-3). The plant marc was extracted with distilled water (AB-4). All the extracts were evaluated for hepatoprotective activity on limited test models as hexobarbitone sleep time, zoxazolamine paralysis time and marker biochemical parameters. AB-1 and AB-2 were observed to be devoid of any hepatoprotective activity. Out of two active extracts (AB-3 and AB-4), the most active AB-4 was studied in detail. AB-4 showed significant hepatoprotective activity against CCl4 induced hepatotoxicity as evident by restoration of serum transaminases, alkaline phosphatase, bilirubin and triglycerides. Hepatoprotective potential was confirmed by the restoration of lipid peroxidation, glutathione, glucose-6-phosphatase and microsomal aniline hydroxylase and amidopyrine N-demethylase towards near normal. Histopathology of the liver tissue further supports the biochemical findings confirming the hepatoprotective potential of AB-4. The present study shows that the aqueous extract of Aloe barbadensis is significantly capable of restoring integrity of hepatocytes indicated by improvement in physiological parameters, excretory capacity (BSP retention) of hepatocytes and also by stimulation of bile flow secretion. AB-4 did not show any sign of toxicity up to oral dose of 2 g/kg in mice.

100 Deals associated with AB-004

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fibrosis, Liver	Preclinical	US	AKSO Biopharmaceutical, Inc.	18 Jun 2024
Renal fibrosis	Preclinical	US	AKSO Biopharmaceutical, Inc.	18 Jun 2024
Idiopathic Pulmonary Fibrosis	Discovery	US	AKSO Biopharmaceutical, Inc.	10 Feb 2022
Nonalcoholic Steatohepatitis	Discovery	US	AKSO Biopharmaceutical, Inc.	10 Feb 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

AB-004

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation